title: Dramatic improvement after rituximab in a patient with paraneoplastic treatment-refractory Morvan syndrome associated with anti-CASPR2 antibodies.
authors.forename: E
authors.initials: E
authors.lastname: Ong
authors.forename: A
authors.initials: A
authors.lastname: Viaccoz
authors.forename: F
authors.initials: F
authors.lastname: Ducray
authors.forename: M
authors.initials: M
authors.lastname: Pérol
authors.forename: G
authors.initials: G
authors.lastname: Cavillon
authors.forename: V
authors.initials: V
authors.lastname: Rogemond
authors.forename: J
authors.initials: J
authors.lastname: Honnorat
authors.forename: P
authors.initials: P
authors.lastname: Petiot
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D001323:Autoantibodies / Q000097:blood*; D004351:Drug Resistance; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008565:Membrane Proteins / Q000276:immunology*; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000276:immunology*; D010257:Paraneoplastic Syndromes / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; C403049:CNTNAP2 protein, human; D007155:Immunologic Factors; D008565:Membrane Proteins; D009419:Nerve Tissue Proteins; D000069283:Rituximab